The polymerase chain reaction (PCR) assay provides a powerful means of detecting minimal residual disease in follicular
The polymerase chain reaction (PCR) assay provides a powerful means of detecting minimal residual disease in follicular lymphoma. Most available data, however, are on stage IV cases.
We tested the blood of 86 patients with stage I-III previously untreated follicular lymphoma before and after therapy with three objectives: (1) to determine the frequency of positive PCR at diagnosis; (2) to examine the correlation of molecular response (conversion to negative PCR in blood) with clinical outcome; and (3) to evaluate the molecular response rate of three different treatment approaches. These consisted of: (1) central lymphatic radiation (mantle plus whole-abdominopelvic radiation) in 23 patients; (2) COP (cyclophosphamide, Oncovin, and prednisone)/CHOP (cyclophosphamide, doxorubicin HCl, Oncovin, and prednisone) with or without involved-field radiation in 43 patients; and (3) chemotherapy alone with an intensive regimen (three alternating combinations [“ATT”]) in 20 patients.
Of 86 patients tested at baseline for both mbr and mcr breakpoints, 74 (86%) were positive in blood. The table below shows the projected failure-free survival (FFS) at 7 years according to the molecular response at 3, 6, and 12 months during therapy:
CONCLUSION: (1) In spite of localized stage, most cases had circulating bcl-2 rearranged cells. (2) Radiation, although a local treatment, resulted in a relatively high systemic molecular response rate. (3) Achievement of early molecular response (3 months) correlated best with clinical outcome. (4) ATT induced a significantly higher molecular response at 3 months, as compared with COP/CHOP with or without radiation.
Click here for Dr. Bruce Cheson’s commentary on this abstract.
Expanding Horizons in T-Cell Lymphoma Therapy: Focus on Personalized Treatment Strategies
Several lymphoma experts discuss the current T-cell lymphoma landscape, the need for new therapies, and ongoing research in the space.
Highlighting Insights From the Marginal Zone Lymphoma Workshop
Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.